DMX-200 Available To Patients Via Post-Trial Access Pathways
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This program aims to support continued treatment for patients with focal segmental glomerular sclerosis who have completed the trial and wish to remain on therapy with physician consultation. The access will be subject to local regulatory frameworks and may involve various pathways such as expanded access or compassionate use. Dimerix emphasizes its commitment to patient continuity of care and addressing unmet medical needs in this population.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Dimerix
- Dimerix exclusively licenses DMX-200 in Greater China, South Korea and Southeast Asia to Everest Medicines
- Dimerix Licenses DMX200 to Everest for China and Asia Region
- Dimerix Quarterly Activities Report and Appendix 4C
- Blinded assessment of ACTION3 statistical assumptions complete
- ACTION3 Statistical Review Complete
Later from Dimerix
- Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
- Dimerix Expands Pipeline with Acquisition of Phase 2 Asset
- Dimerix expands pipeline with acquisition of Phase 2 ready asset for acute kidney injury
- US Patent Granted for Dimerix New Asset DMX-652
- Dimerix Presents at Bioshares Summit 2026
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix